Idarubicin‐loaded beads for chemoembolisation of hepatocellular carcinoma: results of theIDASPHEREphase I trial
Authors:
Open Access
- 16 April 2014
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 39 (11) , 1301-1313
Abstract
Summary: Background: A phase I dose‐escalation trial of transarterial chemoembolisation (TACE) with idarubicin‐loaded beads was performed in cirrhotic patients with hepatocellular carcinoma (HCC).Aim: To estimate the maximum‐tolerated dose (MTD) and to assess safety, efficacy, pharmacokinetics and quality of life.Methods: Patients received a single TACE session with injection of 2 mL drug‐eluting beads (DEBs; DC Bead 300–500 μm) loaded with idarubicin. The idarubicin dose was escalated according to a modified continuous reassessment method. MTD was defined as the dose level closest to that causing dose‐limiting toxicity (DLT) in 20% of patients.Results: Twenty‐one patients were enrolled, including nine patients at 5 mg, six patients at 10 mg, and six patients at 15 mg. One patient at each dose level experiencedDLT(acute myocardial infarction, hyperbilirubinaemia and elevated aspartate aminotransferase (AST) at 5‐, 10‐ and 15‐mg, respectively). The calculatedMTDof idarubicin was 10 mg. The most frequent grade ≥3 adverse events were pain, elevatedAST, elevated γ‐glutamyltranspeptidase and thrombocytopenia. At 2 months, the objective response rate was 52% (complete response, 28%, and partial response, 24%) by modified Response Evaluation Criteria in Solid Tumours. The median time to progression was 12.1 months (95%CI7.4 months – not reached); the median overall survival was 24.5 months (95%CI14.7 months – not reached). Pharmacokinetic analysis demonstrated the ability ofDEBs to release idarubicin slowly.Conclusions: Using drug‐eluting beads, the maximum‐tolerated dose of idarubicin was 10 mg perTACEsession. Encouraging responses and median time to progression were observed. Further clinical investigations are warranted (NCT01040559).Keywords
This publication has 33 references indexed in Scilit:
- Screening of anticancer drugs for chemoembolization of hepatocellular carcinomaAnti-Cancer Drugs, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V StudyCardioVascular and Interventional Radiology, 2009
- Expression of multidrug resistance‐associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell originLiver International, 2008
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001
- Clinical Pharmacokinetics of IdarubicinClinical Pharmacokinetics, 1993
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993